Skip Navigation


NDT Advance Access originally published online on May 3, 2005
Nephrology Dialysis Transplantation 2005 20(7):1378-1384; doi:10.1093/ndt/gfh781
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/7/1378    most recent
gfh781v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Eto, N.
Right arrow Articles by Yamashita, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eto, N.
Right arrow Articles by Yamashita, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Original Article

Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure

Nobuaki Eto, Yoko Miyata, Hiroaki Ohno and Takeyoshi Yamashita

Pharmaceutical Research Laboratories, Kirin Brewery Co., Ltd, 3 Miyahara, Takasaki, Gunma, 370-1295 Japan

Correspondence and offprint requests to: Takeyoshi Yamashita, PhD, Senior Scientist, Nephrology, Pharmaceutical Research Labs, KIRIN Brewery Co. Ltd, Miyahara 3, Takasaki, Gunma 370-1295, Japan. Email: tyamashita{at}kirin.co.jp

Background. Nicotinamide has been shown to inhibit intestinal sodium-dependent phosphate transport activity in normal rats. It was reported recently that type IIb sodium-dependent phosphate co-transporter (NaPi-2b) is a carrier of intestinal phosphate absorption, and that its expression level is regulated by serum 1,25-dihydroxyvitamin D [1,25(OH)2D] and Pi levels in normal rats. However, in chronic renal failure (CRF), serum 1,25(OH)2D and Pi levels are often abnormal. In a rat model of CRF, we investigated whether short-term nicotinamide administration was effective in reducing intestinal phosphate absorption and, if so, whether the effect was mediated by intestinal NaPi-2b.

Methods. Adenine-induced CRF rats were given a single daily intrapenitoneal administration of nicotinamide or vehicle solution for 6 days, and time course changes in serum Pi, Ca, blood urea nitrogen (BUN) and creatinine levels were monitored. Intestinal phosphate absorption was examined by oral administration of radiolabelled phosphate on the final day. In addition, NaPi-2b protein content in jejunum brush border membranes was determined.

Results. Nicotinamide prevented the progressive increase in serum Pi associated with renal failure and significantly inhibited intestinal Pi absorption as assessed by the influx of orally administered radiolabelled phosphate into the circulation. This effect was accompanied by a decrease in NaPi-2b expression in jejunum brush border membranes. In addition, nicotinamide treatment was also associated with less marked elevations in BUN and serum creatinine and a higher creatinine clearance.

Conclusions. Nicotinamide inhibited intestinal Pi absorption in a rat model of CRF, at least in part by inhibiting the expression of NaPi-2b, and appeared to protect against the deterioration of renal function.

Keywords: chronic renal failure; hyperphosphataemia; intestinal phosphate absorption; NaPi; nicotinamide


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
Y. Sabbagh, S. P. O'Brien, W. Song, J. H. Boulanger, A. Stockmann, C. Arbeeny, and S. C. Schiavi
Intestinal Npt2b Plays a Major Role in Phosphate Absorption and Homeostasis
J. Am. Soc. Nephrol., November 1, 2009; 20(11): 2348 - 2358.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
S. J. Onufrak, A. Bellasi, F. Cardarelli, V. Vaccarino, P. Muntner, L. J. Shaw, and P. Raggi
Investigation of Gender Heterogeneity in the Associations of Serum Phosphorus With Incident Coronary Artery Disease and All-Cause Mortality
Am. J. Epidemiol., January 1, 2009; 169(1): 67 - 77.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
S. C. Cheng, D. O. Young, Y. Huang, J. A. Delmez, and D. W. Coyne
A Randomized, Double-Blind, Placebo-Controlled Trial of Niacinamide for Reduction of Phosphorus in Hemodialysis Patients
Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1131 - 1138.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
P. P. How, D. L. Mason, and A. H. Lau
Current Approaches in the Treatment of Chronic Kidney Disease Mineral and Bone Disorder
Journal of Pharmacy Practice, June 1, 2008; 21(3): 196 - 213.
[Abstract] [PDF]

Home page
 CJASNHome page
D. Muller, H. Mehling, B. Otto, R. Bergmann-Lips, F. Luft, J. Jordan, and R. Kettritz
Niacin Lowers Serum Phosphate and Increases HDL Cholesterol in Dialysis Patients
Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1249 - 1254.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.